Boehringer Mannheim gets bedside myocardial infarction (MI) test go-ahead
This article was originally published in Clinica
The US FDA has cleared Boehringer Mannheim's disposable bedside heart attack test, Cardiac T Rapid. Canada-based Spectral Diagnostics was the first to launch a bedside MI test, following US approval of its CK-MB/myoglobin panel in March (see Clinica No 644, p 18), but the Boehringer kit is the first to use cardiac-specific troponin antibodies.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.